Source: Eur Respir J, 50 (4) 1700711; 10.1183/13993003.00711-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roberto W. Dal Negro, Jadwiga A. Wedzicha, Martin Iversen, Giovanni Fontana, Clive Page, Arrigo F. Cicero, Edoardo Pozzi, Peter M.A. Calverley. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J, 50 (4) 1700711; 10.1183/13993003.00711-2017

Member's Comments

No comment yet.

Related content which might interest you: Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). Source: International Congress 2017 – COPD management Year: 2017 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study Source: International Congress 2018 – COPD management Year: 2018 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis Source: Eur Respir Rev 2015; 24: 451-461 Year: 2015 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients Source: International Congress 2017 – COPD management Year: 2017 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015